Background: Inflammatory rhabdomyoblastic tumour (IRMT) is the new consensus terminology in the upcoming 6 th edition of the World Health Organization Classification of Tumours, 1 replacing the previously described entity “inflammatory leiomyosarcoma”. It is a very rare and the only known skeletal muscle tumour of borderline malignancy with less than 50 cases reported in the literature. 1,2
Jia et al. (Sun,) studied this question.